TW201336863A - 具有hiv成熟抑制活性之c-3環烯三萜類化合物 - Google Patents

具有hiv成熟抑制活性之c-3環烯三萜類化合物 Download PDF

Info

Publication number
TW201336863A
TW201336863A TW102105203A TW102105203A TW201336863A TW 201336863 A TW201336863 A TW 201336863A TW 102105203 A TW102105203 A TW 102105203A TW 102105203 A TW102105203 A TW 102105203A TW 201336863 A TW201336863 A TW 201336863A
Authority
TW
Taiwan
Prior art keywords
alkyl
group
mmol
substituted
cyclopenta
Prior art date
Application number
TW102105203A
Other languages
English (en)
Chinese (zh)
Inventor
傑卡布 史威朵斯基
尼可拉斯A 明威
藍恩 艾立西亞 里圭洛
席辛元
陳潔
陳彥
Original Assignee
必治妥美雅史谷比公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48946098&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TW201336863(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 必治妥美雅史谷比公司 filed Critical 必治妥美雅史谷比公司
Publication of TW201336863A publication Critical patent/TW201336863A/zh

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J53/00Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by condensation with a carbocyclic rings or by formation of an additional ring by means of a direct link between two ring carbon atoms, including carboxyclic rings fused to the cyclopenta(a)hydrophenanthrene skeleton are included in this class
    • C07J53/002Carbocyclic rings fused
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J63/00Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
    • C07J63/008Expansion of ring D by one atom, e.g. D homo steroids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
TW102105203A 2012-02-15 2013-02-08 具有hiv成熟抑制活性之c-3環烯三萜類化合物 TW201336863A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261599040P 2012-02-15 2012-02-15
US13/760,726 US8906889B2 (en) 2012-02-15 2013-02-06 C-3 cycloalkenyl triterpenoids with HIV maturation inhibitory activity

Publications (1)

Publication Number Publication Date
TW201336863A true TW201336863A (zh) 2013-09-16

Family

ID=48946098

Family Applications (1)

Application Number Title Priority Date Filing Date
TW102105203A TW201336863A (zh) 2012-02-15 2013-02-08 具有hiv成熟抑制活性之c-3環烯三萜類化合物

Country Status (26)

Country Link
US (1) US8906889B2 (enExample)
EP (1) EP2814834B1 (enExample)
JP (1) JP6155285B2 (enExample)
KR (1) KR20140123584A (enExample)
CN (2) CN104220451B (enExample)
AR (1) AR089996A1 (enExample)
AU (1) AU2013221725B2 (enExample)
BR (1) BR112014019672A8 (enExample)
CA (1) CA2864656A1 (enExample)
CL (1) CL2014002141A1 (enExample)
CO (1) CO7061077A2 (enExample)
EA (1) EA024361B1 (enExample)
ES (1) ES2656984T3 (enExample)
HK (1) HK1204608A1 (enExample)
IL (1) IL234077A (enExample)
MX (1) MX2014009235A (enExample)
MY (1) MY166793A (enExample)
NZ (1) NZ631408A (enExample)
PE (1) PE20142315A1 (enExample)
PH (1) PH12014501816A1 (enExample)
PT (1) PT2814834T (enExample)
SG (1) SG11201404748XA (enExample)
TW (1) TW201336863A (enExample)
UY (1) UY34627A (enExample)
WO (1) WO2013123019A1 (enExample)
ZA (1) ZA201406724B (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8889854B2 (en) 2012-05-07 2014-11-18 Bristol-Myers Squibb Company C-17 bicyclic amines of triterpenoids with HIV maturation inhibitory activity
SG11201505639SA (en) 2013-02-06 2015-08-28 Bristol Myers Squibb Co C-19 modified triterpenoids with hiv maturation inhibitory activity
PL3129392T3 (pl) 2014-04-11 2021-04-06 VIIV Healthcare UK(No.4) Limited Triterpenoidy o aktywności hamującej dojrzewanie hiv, podstawione w pozycji 3 niearomatycznym pierścieniem zawierającym podstawnik fluorowcoalkilowy
WO2015195776A1 (en) 2014-06-19 2015-12-23 Bristol-Myers Squibb Company Betulinic acid derivatives with hiv maturation inhibitory activity
US10047118B2 (en) 2014-11-14 2018-08-14 VIIV Healthcare UK (No.5) Limited C17-aryl substituted betulinic acid analogs
US9969767B2 (en) 2014-11-14 2018-05-15 VIIV Healthcare UK (No.5) Limited Oxolupene derivatives
CN107250151A (zh) * 2014-11-14 2017-10-13 Viiv保健英国第五有限公司 扩展的桦木酸类似物
US10221208B2 (en) * 2015-04-14 2019-03-05 ViiV Healthcare UK (No.4) Limited Methods of producing an HIV maturation inhibitor
WO2017017609A1 (en) 2015-07-28 2017-02-02 Glaxosmithkline Intellectual Property (No.2) Limited Betuin derivatives for preventing or treating hiv infections
CA2993758A1 (en) 2015-07-28 2017-02-02 Glaxosmithkline Intellectual Property (No.2) Limited Betuin derivatives for preventing or treating hiv infections
AU2016327169A1 (en) 2015-09-24 2018-04-12 Glaxosmithkline Intellectual Property (No.2) Limited Compounds with hiv maturation inhibitory activity
EP3405474A1 (en) * 2016-01-20 2018-11-28 Glaxosmithkline Intellectual Property (No. 2) Limited Amine derivatives of lupanes with hiv maturation inhibitory activity
AR107512A1 (es) * 2016-02-04 2018-05-09 VIIV HEALTHCARE UK Nº 5 LTD Triterpenoides modificados en c-3 y c-17 como inhibidores del vih-1
CN106905264B (zh) * 2017-04-12 2019-06-07 连云港杰瑞药业有限公司 一种合成阿扎拉韦中间体的方法
IL273078B2 (en) * 2017-09-13 2025-06-01 Emmyon Inc Ursolic acid morpholine and diethanolamine salts
EP4321164A3 (en) 2018-04-24 2024-04-17 ViiV Healthcare UK (No.5) Limited Compounds with hiv maturation inhibitory activity
CN109705189B (zh) * 2018-12-29 2020-06-05 中国医学科学院药用植物研究所 具有式i所示结构的三萜衍生物及其制备方法和应用
HRP20231582T1 (hr) 2019-02-11 2024-03-15 Hetero Labs Limited Novi derivati triterpena kao inhibitori hiv-a
WO2020229398A1 (de) 2019-05-14 2020-11-19 Bayer Aktiengesellschaft (1-alkenyl)-substituierte pyrazole und triazole als schädlingsbekämpfungsmittel

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5413999A (en) 1991-11-08 1995-05-09 Merck & Co., Inc. HIV protease inhibitors useful for the treatment of AIDS
US5869535A (en) 1995-03-21 1999-02-09 The Board Of Trustees Of The University Of Illinois Method and composition for selectively inhibiting melanoma
US5962527A (en) 1995-03-21 1999-10-05 The Board Of Trustees Of The University Of Illinois Method and composition for treating cancers
US5679828A (en) 1995-06-05 1997-10-21 Biotech Research Labs, Inc. Betulinic acid and dihydrobetulinic acid derivatives and uses therefor
US20040110785A1 (en) 2001-02-02 2004-06-10 Tao Wang Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives
US7365221B2 (en) 2002-09-26 2008-04-29 Panacos Pharmaceuticals, Inc. Monoacylated betulin and dihydrobetulin derivatives, preparation thereof and use thereof
WO2004089357A2 (en) 2003-04-02 2004-10-21 Regents Of The University Of Minnesota Anti-fungal formulation of triterpene and essential oil
US7745625B2 (en) 2004-03-15 2010-06-29 Bristol-Myers Squibb Company Prodrugs of piperazine and substituted piperidine antiviral agents
MXPA06010592A (es) 2004-03-17 2007-06-12 Panacos Pharmaceuticals Inc Sales farmaceuticas de acido 3-o-(3',3'-dimetilsuccinil) betulinico.
TW200628161A (en) 2004-11-12 2006-08-16 Panacos Pharmaceuticals Inc Novel betulin derivatives, preparation thereof and use thereof
WO2008127364A2 (en) 2006-10-13 2008-10-23 Myriad Genetics, Inc. Antiviral compounds and use thereof
US20110144069A1 (en) 2006-10-16 2011-06-16 Myriad Genetics, Incorporated Compounds for treating viral infections
WO2009020732A1 (en) 2007-08-03 2009-02-12 Advanced Life Sciences, Inc. Lupane-type triterpenoids modified at 30-position and analogues thereof
WO2009082819A1 (en) * 2008-01-03 2009-07-09 Virochem Pharma Inc. Novel lupane derivatives
EP2257567A1 (en) 2008-02-14 2010-12-08 Virochem Pharma Inc. Novel 17 beta lupane derivatives
US9067966B2 (en) 2009-07-14 2015-06-30 Hetero Research Foundation, Hetero Drugs Ltd. Lupeol-type triterpene derivatives as antivirals
MA33926B1 (fr) 2009-12-17 2013-01-02 Merck Sharp & Dohme Aminopyrimidines en tant qu'inhibiteurs de la syk
MX2012013628A (es) 2010-06-04 2012-12-17 Bristol Myers Squibb Co Amidas c-28 de derivados del acido betulinico c-3 modificados como inhibidores de la maduracion del virus de inmunodeficiencia humana (vih).
CN103038245B (zh) * 2010-06-04 2015-03-25 百时美施贵宝公司 作为hiv成熟抑制剂的c-3经修饰的桦木酸衍生物
MA34397B1 (fr) 2010-07-02 2013-07-03 Gilead Sciences Inc Dérivés d'acide napht-2-ylacétique dans le traitement du sida
US8846647B2 (en) 2011-01-31 2014-09-30 Bristol-Myers Squibb Company C-17 and C-3 modified triterpenoids with HIV maturation inhibitory activity
RS54352B1 (sr) 2011-01-31 2016-02-29 Bristol-Myers Squibb Company C-28 amini c-3 modifikovanih derivata betulinske kiseline kao inhibitori sazrevanja hiv-a
BR112014006559A2 (pt) * 2011-09-21 2017-03-28 Bristol Myers Squibb Co derivados do ácido betulínico com atividade antiviral
US8889854B2 (en) * 2012-05-07 2014-11-18 Bristol-Myers Squibb Company C-17 bicyclic amines of triterpenoids with HIV maturation inhibitory activity
SG11201505639SA (en) * 2013-02-06 2015-08-28 Bristol Myers Squibb Co C-19 modified triterpenoids with hiv maturation inhibitory activity

Also Published As

Publication number Publication date
KR20140123584A (ko) 2014-10-22
CN104220451B (zh) 2016-06-29
AU2013221725A1 (en) 2014-10-02
IL234077A (en) 2016-11-30
UY34627A (es) 2013-09-02
US8906889B2 (en) 2014-12-09
WO2013123019A1 (en) 2013-08-22
IL234077A0 (en) 2014-09-30
MX2014009235A (es) 2014-11-10
CN106046106A (zh) 2016-10-26
JP2015510515A (ja) 2015-04-09
EA201491531A1 (ru) 2014-11-28
US20130210787A1 (en) 2013-08-15
CA2864656A1 (en) 2013-08-22
AR089996A1 (es) 2014-10-01
BR112014019672A8 (pt) 2017-07-11
EA024361B1 (ru) 2016-09-30
CL2014002141A1 (es) 2014-10-03
PT2814834T (pt) 2017-12-06
NZ631408A (en) 2015-06-26
AU2013221725B2 (en) 2016-10-27
CN104220451A (zh) 2014-12-17
SG11201404748XA (en) 2014-09-26
MY166793A (en) 2018-07-23
JP6155285B2 (ja) 2017-06-28
CO7061077A2 (es) 2014-09-19
PE20142315A1 (es) 2015-01-16
ZA201406724B (en) 2016-08-31
PH12014501816A1 (en) 2014-11-17
EP2814834A1 (en) 2014-12-24
EP2814834B1 (en) 2017-09-13
ES2656984T3 (es) 2018-03-01
BR112014019672A2 (enExample) 2017-06-20
HK1204608A1 (en) 2015-11-27

Similar Documents

Publication Publication Date Title
JP6155285B2 (ja) Hiv成熟阻害活性のあるc−3シクロアルケニルトリテルペノイド
JP6186012B2 (ja) C−3アルキルおよびアルケニル修飾ベツリン酸誘導体
CA2801491C (en) C-28 amides of modified c-3 betulinic acid derivatives as hiv maturation inhibitors
JP5752789B2 (ja) Hiv成熟阻害剤としての修飾c−3ベツリン酸誘導体
US11464790B2 (en) Triterpenoids with HIV maturation inhibitory activity
TWI574973B (zh) 具有hiv成熟抑制活性之c-17雙環胺三萜類化合物
HK40041853A (en) Triterpenoids with hiv maturation inhibitory activity
HK1232548B (en) Triterpenoids with hiv maturation inhibitory activity, substituted in position 3 by a non-aromatic ring carrying a haloalkyl substituent